Semaglutide

Semaglutide is a GLP-1 receptor agonist peptide that suppresses appetite, increases satiety, and improves glucose metabolism for pharmaceutical-grade weight loss and blood sugar control, achieving average weight loss of 15-18% body weight (30-40+ pounds) over 6 months in individuals with obesity or diabetes through sustained once-weekly injections or oral dosing. FDA-approved for both type 2 diabetes (as Ozempic) and weight management (as Wegovy), it outperforms all prior GLP-1 agonists including liraglutide with superior efficacy and sustained action.

Route

Subcutaneous injection

Dose range

250 mcg – 2.4 mg

Frequency

Once per week (subcutaneous)

Cycle length

Long-term management involves titrating to maintenance

GLP-S 5MG
N1 AminosLab tested · CoA

GLP-S 5MG

Third-party tested, lot traceable, ships in 3–5 business days.

$29.00per vial$26.00/vial at 5+
View →

Overview

Semaglutide is a GLP-1 receptor agonist peptide that suppresses appetite, increases satiety, and improves glucose metabolism for pharmaceutical-grade weight loss and blood sugar control, achieving average weight loss of 15-18% body weight (30-40+ pounds) over 6 months in individuals with obesity or diabetes through sustained once-weekly injections or oral dosing. FDA-approved for both type 2 diabetes (as Ozempic) and weight management (as Wegovy), it outperforms all prior GLP-1 agonists including liraglutide with superior efficacy and sustained action.

Clinical advantages include once-weekly dosing convenience, sustained appetite suppression lasting days, improved cardiovascular outcomes in diabetes, renal protection, and metabolic improvements beyond pure weight loss. Users report reduced hunger, increased fullness from smaller portions, improved blood sugar stability, and sustained energy as metabolism optimizes. Gastrointestinal side effects (nausea, constipation) are transient and dose-manageable. For individuals with type 2 diabetes, obesity, or metabolic syndrome seeking pharmaceutical-grade weight loss with cardiovascular and longevity benefits, Semaglutide offers transformation through appetite and glucose regulation.

Studied benefits

  • A once-weekly injection that promotes significant weight loss (10–15% on average) and improves blood sugar control
  • It also offers proven cardiovascular benefits, reducing the risk of major heart-related events

Reported side effects

  • Most common are gastrointestinal issues like nausea and abdominal pain, which typically improve with gradual dose increases
  • Rare but serious risks include pancreatitis and gallbladder disease

Protocol

Dosing Schedule (Subcutaneous)

Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.

Semaglutide (5mg)

Reconstitute with 2.0 mL bacteriostatic water (Final concentration: ~2.5 mg/mL).

Support chronic weight management through GLP-1 receptor activation, leading to reduced appetite and improved metabolic parameters.

Semaglutide (10mg)

Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~3.33 mg/mL).

Support chronic weight management through GLP-1 receptor activation and reduced gastric emptying.

Semaglutide (20mg)

Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~6.67 mg/mL).

Support chronic weight management and improved metabolic parameters through potent GLP-1 receptor agonism.

WeekWeekly DoseDraw at 2.5 mg/mLLog
Weeks 1–4250 mcg (0.25 mg)10 units (0.1 mL)+ Log
Weeks 5–8500 mcg (0.5 mg)20 units (0.2 mL)+ Log
Weeks 9–121000 mcg (1.0 mg)40 units (0.4 mL)+ Log
Weeks 13–161700 mcg (1.7 mg)68 units (0.68 mL)+ Log
Weeks 17+2400 mcg (2.4 mg)96 units (0.96 mL)+ Log

Frequency

Once per week (subcutaneous).

Timing

Consistent day of the week; rotate injection sites.

Cycle length

Long-term management involves titrating to maintenance.

Unit calculator

Set your vial and water; the table above updates.

Open the full calculator →
Concentration

2.5 mg/mL

20 doses of 250 mcg per vial

Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.

Context

Lifestyle considerations

Maintain a high-protein diet to mitigate the risk of muscle loss while this GLP-1 receptor agonist significantly reduces caloric intake through delayed gastric emptying and increased satiety. Incorporate regular resistance training to provide a stimulus for muscle preservation during rapid weight loss. Ensure 7–9 hours of quality sleep to optimize metabolic health and prevent cortisol-driven hunger cues. Maintain optimal hydration and monitor progress through measurements beyond just weight (such as body fat percentage) to ensure the weight loss is primarily coming from adipose tissue rather than lean mass.

Evidence

Research summaries

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

Findings: Keeps weight off for over 2 years, shrinks waist, and steadies blood sugar—huge for staying healthy long-haul.

Over 300 adults with extra weight (no diabetes) got weekly Semaglutide shots plus diet tips for 2 years. They lost 15% body weight vs. 2.4% on fake shots! 77% hit 5%+ loss, waist slimmed 14cm, blood pressure dropped. Belly issues were main side (mild), but quit rates low. Unlike quick diets, weight stayed off—no rebound. For teens watching weight, it's proof steady hormone help + habits = real change. Also hints at delaying diabetes by fixing sugar swings early.

Read the study ↗

Weight Loss Outcomes and Semaglutide Treatment for Patients With Overweight or Obesity

Findings: Drops pounds fast (5-10% in months), more in non-diabetics, easing joint strain and energy boosts.

Real-world check on 18,000+ patients using Semaglutide like in trials. In 3 months, 1mg dose shed 4%, 2.4mg hit 5%; by 7 months, 7-10%. Non-diabetics lost more (maybe less calorie burn drop). Helps heart by cutting fat weight. Ties to better sugar control via less pee-sugar loss. Imagine carrying less backpack all day—you move easier. Safe for ongoing use, but watch tummy upset at start.

Read the study ↗

Long-term weight loss effects of semaglutide in obesity without diabetes (SELECT trial analysis)

Findings: Cuts major heart events 20% while trimming weight, perfect for overweight with heart worries.

Huge trial of 17,000+ overweight adults (no diabetes, but heart history). Semaglutide slashed heart attacks/strokes 20%, plus ~10% weight loss sustained. Not just thin—safer ticker. Blood sugar improved too. For active kids, shows fixing weight early guards heart from sports strains or family history. Mild gut sides, but benefits outweigh.

Read the study ↗

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight

Findings: Stopping regain—keeps loss going vs. ballooning back up on placebo.

After 5 months loss on Semaglutide, half kept it, half switched placebo. Keepers lost another 8%; switchers regained most. 90%+ stayed in study. Proves sticking with it prevents yo-yo. Great life lesson: consistency wins. Waist, sugar, lipids all improved more.

Read the study ↗
More references (3)

Identification

Chemistry

cas
910463-68-2 (free base)
formula
C₁₈₇H₂₉₁N₄₅O₅₉
molecular weight
4113.64 g/mol (also reported as 4111.1154 exact mass, 4100 Da average)
sequence
Modified GLP-1 sequence (31 amino acids, positions 7-37 numbered from full native GLP-1); first 6 N-terminal amino acids of native GLP-1 are missing
source
Synthetic; engineered GLP-1 analog derived from natural human GLP-1 hormone
biosynthesis
Non-ribosomal; chemically synthesized via solid-phase peptide synthesis (SPPS) with post-synthetic acylation
type
Linear peptide with N-terminal amino group and C-terminal carboxylic acid; acylated with C-18 fatty acid chain

Keep exploring

Related peptides

Educational use only. The protocols shown summarise published research and community practice for informational purposes. They are not medical advice, not a prescription, and not a recommendation to use any compound. Research peptides are generally not approved for human use. Consult a licensed clinician. Full disclaimer.
Ask the advisor